

Attorney Docket: 2260/50666

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: TOSHIO KASAMA ET AL

Serial No.: To Be Assigned Group Art Unit:

Filed:

Herewith

Examiner:

Title:

OPHTHALMIC OINTMENTS FOR TREATING INFECTIVE EYE

DISEASES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:


In accordance with the duty of disclosure under 37 CFR \$1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application. Copies are not enclosed because they were supplied by the International Bureau.

The present Information Disclosure Statement is being filed

(1) no later than three months from the application's filing

date or (2) before the mailing date of the first Office Action

on the merits (whichever is later), and therefore no



certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted

Herbert I. Cantor

Registration No. 24,392

CROWELL & MORING, LLP

P.O. Box 14300

Washington, DC 20044-4300

Telephone No.: (202) 624-2500 Facsimile No.: (202) 628-8844

.